MedTrace Logo

Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea

NCT00480974 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2009-09-04

No results posted yet for this study

Summary

Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood.

Conditions

Interventions

OTHER

Clinical follow up and laboratory analysis

Clinical follow up and laboratory analysis

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Ariel Koren, MD · Pediatric Hematology Unit, Ha'Emek Medical Center

  • Carina Levin, MD · Pediatric Hematology Unit - Ha'Emek Medical Center

  • Miri Golan, Student · Pediatric Hematology Unit - HaEmek Medical Center

  • Luci Zalman, PhD · Hematology Laboratory - HaEmek Medical Center

Eligibility

Min Age
5 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00480974 on ClinicalTrials.gov